Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab
Active, not recruiting
M.D. Anderson Cancer Center
The goal of this clinical research study is to see how well the drugs 2CdA,
cyclophosphamide, and rituximab (rituxan) shrink a lymphoma called Waldenstrom's
macroglobulinemia. After these drugs are given for 2 courses, a second goal is to see how
long a remission lasts. A third goal is to see how often repeat remissions can be achieved
when the lymphoma returns later and the same drugs are restarted.
Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia
New York Medical College
CLAG-M is an active, well tolerated regimen in acute myelogenous leukemia. Each of the
agents is active in Acute Lymphoblastic Leukemia (ALL) as well. The current trial will
determine the efficacy of the regimen in patients with relapsed ALL.
Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm
Not yet recruiting
National Cancer Institute (NCI)
This randomized pilot trial studies how well higher or lower dose cladribine, cytarabine,
and mitoxantrone work in treating medically less fit patients with newly diagnosed acute
myeloid leukemia or myeloid neoplasm. Drugs used in chemotherapy, such as cladribine,
cytarabine, and mitoxantrone, work in different ways to stop the growth of cancer cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. It is not yet known whether giving cladribine, cytarabine, and mitoxantrone at
higher or lower dose may work better in treating patients with newly diagnosed acute myeloid
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.